In a report released today, Matthew O’Brien from Piper Sandler reiterated a Hold rating on Humacyte (HUMA – Research Report), with a price target of $3.00. The company’s shares opened today at $2.26.
O’Brien covers the Healthcare sector, focusing on stocks such as Stryker, Sight Sciences, and Alphatec Holdings. According to TipRanks, O’Brien has an average return of 2.2% and a 46.68% success rate on recommended stocks.
Currently, the analyst consensus on Humacyte is a Strong Buy with an average price target of $7.17.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.60 and a one-year low of $1.96. Currently, Humacyte has an average volume of 713.3K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUMA in relation to earlier this year. Last month, Dougan Brady W, a Director at HUMA bought 114,420.00 shares for a total of $136,159.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
- Humacyte Third Quarter 2023 Financial Results and Business Update
- Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
- Humacyte publishes preclinical study on HAV to treat Tetralogy of Fallot
- Humacyte to Present at the Cantor Global Healthcare Conference
- Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
